In contrast to the relatively smaller outbreaks of SARS-CoV in 2002 and MERS-CoV in 2012, SARS-CoV-2 is exhibiting an unprecedented scale of infection, resulting in a global pandemic declaration of Coronavirus Infectious Disease (COVID-19) on 11 March 2020 by the World Health Organization (WHO)
Attach a new needle to the pen
If you have nausea, constipation, fatigue, or other GLP-1 side effects, Potere Health MD provides ongoing support to help you adjust safely
Chemical Name: CagriSema (dual-agonist research peptide blend) Active Components: Cagrilintide (amylin analogue) Semaglutide (GLP-1 receptor agonist) (Combined for dual metabolic pathway research) Molecular Formulas: Proprietary peptide analogs (individual peptides each have distinct formulas based on sequence) Molecular Weights: Cagrilintide: ~4,409 g/mol (as commonly listed for the analog form) Semaglutide: ~4,186 g/mol (typical peptide GLP-1 analog) CAS Numbers: Not standardized for the blended research product (individual active peptides have separate registry identifiers) Classification: Synthetic research peptide blend (dual GLP-1 and amylin receptor agonist analogs) Purity: 99 % (HPLC-verified research grade
Este producto es un Suplemento alimenticio, solo se debe consumir con fines de suplementar la dieta, no reemplaza una alimentacin balanceada
This study received no external funding
